In short
Muvalaplin is an investigational oral medicine being studied to lower elevated lipoprotein(a), or Lp(a), a type of fat in the blood linked to cardiovascular disease. A Phase 3 clinical trial is currently suspended after enrolling 10,450 adults with elevated Lp(a) and atherosclerotic cardiovascular disease. The trial is testing whether muvalaplin reduces major adverse cardiac events compared with placebo.
Key points
- Muvalaplin is a small molecule inhibitor of lipoprotein(a) formation, taken as a tablet by mouth.
- The pivotal Phase 3 trial enrolled 10,450 adults with elevated Lp(a) and atherosclerotic cardiovascular disease.
- The trial is currently suspended, according to the EU Clinical Trials Information System.
- The primary endpoint is time to first occurrence of the MACE-4 composite of major adverse cardiac events.
- Muvalaplin has no marketing authorisation and remains an investigational substance.
What is muvalaplin?
Muvalaplin is a chemically synthesised, small molecule investigational substance supplied by Eli Lilly and Company Limited. It is described in the medical literature as a daily oral small molecule inhibitor of lipoprotein(a), being studied in high-risk cardiovascular patients with elevated lipoprotein(a) levels. Muvalaplin has no marketing authorisation in the product records and remains an investigational substance.
How does muvalaplin work?
Muvalaplin is an inhibitor of lipoprotein(a) formation. Lipoprotein(a), abbreviated Lp(a), is a particle in the blood made up of fats and proteins. High levels of Lp(a) are associated with an increased risk of atherosclerotic cardiovascular disease, which is the build-up of fatty deposits in the arteries that can lead to heart attacks and strokes. By reducing the formation of Lp(a), muvalaplin is intended to lower the amount of this particle circulating in the blood.
Which conditions is it studied for?
- Elevated lipoprotein(a) — higher than normal levels of Lp(a), a fat-carrying particle in the blood that raises cardiovascular risk.
- Atherosclerotic cardiovascular disease (ASCVD) — a condition in which fatty deposits build up inside the arteries, increasing the chance of heart attack and stroke.
How is muvalaplin given?
In the clinical trial records, muvalaplin is formulated as a tablet for oral use. The supplementary literature describes it as a daily oral medicine.
What do the clinical trials show?
One Phase 3 trial is registered for muvalaplin in the EU Clinical Trials Information System. The trial enrolled 10,450 adults with elevated Lp(a) and atherosclerotic cardiovascular disease. Participants receive muvalaplin as a tablet by mouth or a placebo to match. The trial is currently suspended, meaning that recruitment or treatment has been paused.
The primary outcome measure is the time to first occurrence of any component of the Major Adverse Cardiac Event (MACE)-4 composite endpoint. A composite endpoint combines several related events into one measure; MACE-4 typically includes events such as heart attack, stroke, and cardiovascular death. The trial is designed to evaluate whether muvalaplin is superior to placebo in reducing the risk of this composite endpoint.
What side effects are known?
The provided sources do not report specific side effects for muvalaplin. As an investigational substance, its safety profile is still being evaluated in clinical trials.